Thursday, August 7, 2014
FDA Greenlights Use of TKM-EBOLA in Current Outbreak
Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.
11 comments:
Does this mean BLT will become a success story? Curing Ebola with one shot is quite something.
It's not like this is the first time this has ever happened... for all those who are bullish about use of experimental medicine in africa, here is a cautionary tale
http://www.washingtonpost.com/wp-dyn/content/article/2006/05/06/AR2006050601338.html
The Pfizer/Nigeria situation was (at least per that article) different in that people weren't informed.
In this case it's not likely TKM-Ebola will be used without the explicit permission of every stakeholder.
That said, the day's (+40%) gains of $TKMR over this news appears to be a bit nonsensical. The results of such a trial aren't likely to meaningfully contribute to the commercial pipeline for infectious disease (i.e.: HBV). Future products will continue to bear the risk of the immuno-stimulation issues inherent with LNP/RNA.
A market cap of 470M doesn't seem excessive when $ALNY is considered (currently ~ $4B), particularly considering their current and potential revenue streams in oncology. However such heavy short term gains in the face of news not likely to bear any commercial significance speaks more to the state of a speculative short-term interest market likely to cool just as quickly as it heated up. This might be a great time to short?
If tkm ebola works well and it probably will it will leap frog rnai into the viral space, remember the current flu vaccine programs are very lax in there testing as a matter of history, this could achieve the same advantage for rnai. It is interesting that shrna also is close to clinical verification with callimmune HIV and BlT HepC, exciting times indeed.
How do we track the current effectiveness if TKMR-Ebola is used more widely in the current outbreak?
I think it will another stars day to shine this week. Maybe tomorrow.
Alnylam is a big constellation.
Pity I can't find anything on a Google search that describes it except as a pharmaceutical company.
http://www.bloomberg.com/news/2014-08-10/new-ebola-drugs-create-debate-over-effects-on-outbreak.html
Sierra Leone has contacted Tekmira...
Most likely outcome, share price aside, is new mutant strain of experimental drug resistant Ebola.
Very true. a bit hasty. May do well temporarily for the stock price. Hopefully, the cytokine storm issue led to FDA hold does not result in detrimental effect to set the RNAi field back again.
It's not like this is the first time this has ever happened...
Does this mean BLT will become a success story?
BLT will never be a success story as things stand or by itself.
When you read that article Dirk posted up, it is clear, the vision of the two main men in BLT is to make a wad of cash and go home. Sounds like a trade sale to me.
There is no mention of the new lab and apparently the toxicity issues of old are still unresolved due to the high number of "events" in the mice subjects.
BLT a success story? And pigs really can fly on Planet Claire.
Post a Comment